DRAK2 Polyclonal Antibody

DAP (death associated protein) kinase and ZIP kinase are members of a novel protein kinase family, the members of which have the capacity to mediate apoptosis through their catalytic activities. DAP kinase contains a "death domain" and has been shown to mediate gamma interferon-induced apoptosis. The introduction of DAP kinase into highly metastatic carcinoma clones lacking DAP kinase expression was shown to result in the suppression of metastasis, thus linking suppression of apoptosis to metastasis. ZIP kinase contains a leucine zipper domain, which is necessary for homodimerization and for interaction with other leucine zipper proteins. ZIP kinase dimerizes with ATF-4, an ATF/CREB transcription factor family member that contains a leucine zipper. DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1) and DRAK2 are DAP kinase related proteins. DRAK1 and DRAK2 are localized to the nucleus, and overexpression of both DRAK proteins in NIH/3T3 cells induces morphological changes associated with apoptosis.

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:40000; IF 1:50-200